Hanmi Pharmaceutical Earnings Beat Expectations – What Drives the Rally? Hanmi Pharmaceutical is rated Buy: revenue +29.3% YoY, gross margin 59.6%, net income +115.2% YoY, but operating profit -36.0% YoY and China receivables governance risk remain. Valuation below average target. 2026년 09월 21일 English
